| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/27/2001 | WO2001064659A3 Indane derivatives and their use as cell adhesion inhibitors |
| 12/27/2001 | WO2001064645A3 Derivatives of quinoline as alpha-2 antagonists |
| 12/27/2001 | WO2001064199A3 Farnesyl protein transferase inhibitor combinations with taxane compounds |
| 12/27/2001 | WO2001062086A8 Nutritional intervention composition for enhancing and extending satiety |
| 12/27/2001 | WO2001060356B1 Method for improving bone modeling and chondrocyte functioning in growing canines |
| 12/27/2001 | WO2001060349B1 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof. |
| 12/27/2001 | WO2001059088A3 Vector |
| 12/27/2001 | WO2001057042A3 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy |
| 12/27/2001 | WO2001055116A3 Quinoline derivatives and their use as aurora 2 kinase inhibitors |
| 12/27/2001 | WO2001053505A3 Herpes virus strains for gene therapy |
| 12/27/2001 | WO2001053268A3 Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation |
| 12/27/2001 | WO2001051489A3 Methods for lowering uric acid levels |
| 12/27/2001 | WO2001049711A3 Nucleic acids encoding (poly)peptides having chips activity |
| 12/27/2001 | WO2001047941A3 Benzophenone alpha-d-glycopyranosides, preparation and therapeutic use |
| 12/27/2001 | WO2001045680A3 Cd45 inhibitors |
| 12/27/2001 | WO2001045650A3 Cosmetic use of the residues from wine production |
| 12/27/2001 | WO2001041771A3 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 12/27/2001 | WO2001040239A3 Transition metal-cyclopentadienyl-tropane conjugates |
| 12/27/2001 | WO2001038490A3 ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA |
| 12/27/2001 | WO2001037813A3 Multilayer preparation for a controlled, pulsed release of active substances |
| 12/27/2001 | WO2001037782A3 Method and composition for the treatment of scars |
| 12/27/2001 | WO2001035975A3 Treatment of subnormal bone mineral density |
| 12/27/2001 | WO2001035957A3 Stable salts of novel derivatives of 3,3-diphenylpropylamines |
| 12/27/2001 | WO2001035952A8 Radiosensitization of human glioblastoma cells by quinazoline compounds |
| 12/27/2001 | WO2001035926A3 An improved pharmaceutical composition for treating male erectile dysfunction |
| 12/27/2001 | WO2001034614A3 Compositions and methods for double-targeting virus infections and targeting cancer cells |
| 12/27/2001 | WO2001032646A3 Sulfonamide derivatives |
| 12/27/2001 | WO2001032191A3 Phytoestrogenic pharmaceutical preparations |
| 12/27/2001 | WO2001030336A3 Pharmaceutical formulations comprising resveratrol and use thereof |
| 12/27/2001 | WO2001029020A3 Neuraminidase inhibitors |
| 12/27/2001 | WO2001028979A3 Inhibitors of neuraminidases |
| 12/27/2001 | WO2001026693A3 Manufacture of polyglutamate-therapeutic agent conjugates |
| 12/27/2001 | WO2001023390A3 Azepinoindole derivatives, the production and use thereof |
| 12/27/2001 | WO2001022917A3 Effervescent compositions comprising nimesulide |
| 12/27/2001 | WO2001021159A3 Pharmaceutical composition of nateglinide and another antidiabetcagent |
| 12/27/2001 | WO2001012204A3 Xanthine oxidase inhibitor containing compositions for the treatment of acetaminophen intoxication |
| 12/27/2001 | WO2001003682A3 Use of pyridoxin derivatives for the treatment of diabetes and related complications |
| 12/27/2001 | WO2000067626A3 Oat extracts: refining, compositions and methods of use |
| 12/27/2001 | WO2000064864A9 N-protected amines and their use as prodrugs |
| 12/27/2001 | WO2000055109A9 Lipoxin compounds and their use |
| 12/27/2001 | WO2000054785A9 Stabilized bicyclo[3.3.1]nonenes and methods of use |
| 12/27/2001 | WO1999056780A8 Isomer enriched conjugated linoleic acid compositions |
| 12/27/2001 | US20010056301 Hydrogel biomedical articles |
| 12/27/2001 | US20010056211 Adrenergic blocking agent |
| 12/27/2001 | US20010056205 3-Methoxybenzyl thiourea derivatives and improved lipid compositions containing same |
| 12/27/2001 | US20010056191 Hydantoin-containing glucokinase activators |
| 12/27/2001 | US20010056184 Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds |
| 12/27/2001 | US20010056183 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 12/27/2001 | US20010056126 Treating nervous system disorders such as attention deficit hyperactivity disorder, or immune system dysfunction due to AIDS, cancer chemotherapy, infections |
| 12/27/2001 | US20010056125 Local anesthetic methods and kits |
| 12/27/2001 | US20010056124 Such as 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol, in free form or as salt to treat organ or tissue allo- or xeno-transplant rejection |
| 12/27/2001 | US20010056122 Therapies for treating pulmonary diseases |
| 12/27/2001 | US20010056121 By administering rosemary or sage extracts; carnosic acid, carnosol |
| 12/27/2001 | US20010056119 Materials and methods for the treatment of depression |
| 12/27/2001 | US20010056118 Induction of polymerization of tubulin and the stabilization of microtubules in cells by administering to the cancer cells an effective amount of dictyostatin-1 or derivatives or salt |
| 12/27/2001 | US20010056116 A prodrug compound capable of facilitating the passage of a drug across the blood brain barrier comprising a fatty acid coupled to a drug to form a prodrug |
| 12/27/2001 | US20010056115 Novel therapeutic method |
| 12/27/2001 | US20010056114 Treating an eye condition associated with angiogenesis in a human or animal comprising administering to the patient an angiogenesis inhibiting amount of EM-138 ( a isoindol-2-one substituted by hydroxy-glutamic acid) |
| 12/27/2001 | US20010056113 Methods for the inhibition of angiogenesis with 6-amino EM-12 |
| 12/27/2001 | US20010056112 Synthetic compounds for treatment of inflammation |
| 12/27/2001 | US20010056110 Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes |
| 12/27/2001 | US20010056108 Nitric oxide scavengers, such as dithiocarbamate-containing compounds, are used to reduce side effects caused by therapeutical administration of nitric oxide sources |
| 12/27/2001 | US20010056107 Cyano and carboxy derivatives of substituted styrenes are inhibitors of tumor necrosis factor alpha , nuclear factor kappa B, and phosphodiesterase and can be used to treat cachexia, endotoxic shock, inflammatory conditions etc. |
| 12/27/2001 | US20010056105 Useful as cosmetic for hair and body hygiene, and for treatment of dermatological complaints, with an inflammatory and/or immunoallergic component of rheumatic or respiratory type, cardivascular and opthalmogical disorders |
| 12/27/2001 | US20010056104 Treatment of ocular hypertension and glaucoma by long-term therapy with a prostaglandin related compound for elimination or reduction of potential iridic pigmentation |
| 12/27/2001 | US20010056103 Non-immunosuppressive, piperidino or pyrrolidino amide derivative has an affinity for an FKBP-type immunophilin, useful for treating Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, amyotrophic lateral sclerosis |
| 12/27/2001 | US20010056102 Crystals of piperidine derivatives, intermediates for production of the same, and process for producing the same |
| 12/27/2001 | US20010056101 Treatment for disorders stemming from dopamine dysfunction, such as psychosis, schizophrenia, and movement disorders by administration of full or partial dopamine agonist together with dopamine antagonist to prevent side effects |
| 12/27/2001 | US20010056100 Carboxylic acid or tetrazole derivatives containing carbamate groups are useful for treating the conditions associated with the urinary tract, pain, inflammation, respiratory states, edema formation of hypotensive vascular diseases |
| 12/27/2001 | US20010056099 Method of reducing morbidity and the risk of mortality |
| 12/27/2001 | US20010056097 Therapeutic agent for dermatitis |
| 12/27/2001 | US20010056095 Salts of zopolrestat |
| 12/27/2001 | US20010056093 Olopatadine and emedastine and an ophthalmically acceptable polymeric quaternary ammonium compound as a preservative |
| 12/27/2001 | US20010056092 Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| 12/27/2001 | US20010056091 Therapeutic use of a thienylcyclohexylamine derivative |
| 12/27/2001 | US20010056087 Use of 5alpha-androst-1en-3,17-diol to increase the level of the anabolic/androgenic hormone 17beta-hydroxy-5alpha-androst-1-en-3-one in humans |
| 12/27/2001 | US20010056086 Aromatase inhibitors, estrogen receptor antagonists |
| 12/27/2001 | US20010056085 Methods of using vesicant drug formulations |
| 12/27/2001 | US20010056084 Analgesic effect is achieved by interaction of said antagonist at peripheral mGluR receptors |
| 12/27/2001 | US20010056082 Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer |
| 12/27/2001 | US20010056081 Treatment of cerebrovascular disease |
| 12/27/2001 | US20010056079 Chitosan and polysaccharide immobilized thereto selected from heparin, heparan sulphate and dextran sulphate for manufacture of agent capable of preventing or reducing undesirable adhesion of damaged tissue in connection with wound healing |
| 12/27/2001 | US20010056078 Novel method for treating gut disorders using polyanionic polyglycosides |
| 12/27/2001 | US20010056077 Pharmaceutical composition for treatment of duchenne muscular dystrophy |
| 12/27/2001 | US20010056076 Treatment of acute lung injury and fibrosis with antagonists of alphavbeta6 |
| 12/27/2001 | US20010056071 Use of resveratrol for the treatment of exfoliative eczema, acne and psoriasis |
| 12/27/2001 | US20010056068 Such as atherosclerosis, restenosis, hypertension, preeclampsia and/or intrauterine fetal growth retardation, infection, SLE-lupus, anaphylactic reaction, allograft rejection, hormone replacement therapy, Alzheimer's disease |
| 12/27/2001 | US20010056065 Drug delivery complex molecule with "parachute" structure which hinders structure from going through the cell membrane and a drug that can penetrate the membrane; for photodynamic therapy and chemotherapy |
| 12/27/2001 | US20010056062 As osmotic agents synthetic polypeptides of two to fifteen amino acids long; slow transport across the peritoneum, for prolonged osmotic gradient between dialysate and blood |
| 12/27/2001 | US20010056060 Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| 12/27/2001 | US20010055809 Media containing pure perfluorocarbon that may be oxygenated |
| 12/27/2001 | US20010055751 PSCA: Prostate stem cell antigen and uses thereof |
| 12/27/2001 | US20010055630 Compostion and methods for treating alzheimer's disease and other amyloidoses |
| 12/27/2001 | US20010055629 Extraction |
| 12/27/2001 | US20010055627 Compositions And Methods For Regulating Lipoproteins And Hypercholesterolemia With Limonoids, Flavonoids And Tocotrienols |
| 12/27/2001 | US20010055616 Multilayer; active material core, enteric coating |
| 12/27/2001 | US20010055614 Osmosis dosage form |
| 12/27/2001 | US20010055613 Oral pulsed dose drug delivery system |
| 12/27/2001 | US20010055612 Extended release formulation |
| 12/27/2001 | US20010055611 Freeze drying |